Cullinan Therapeutics, Inc. Common Stock
CGEMCullinan Therapeutics, Inc. (CGEM) is a biotechnology company focused on developing gene editing and gene therapy technologies to treat genetic and chronic diseases. The company aims to leverage advanced research platforms to create innovative therapeutic solutions with a focus on precision medicine.
Company News
Cullinan Therapeutics presented preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, demonstrating potential for B cell depletion across multiple autoimmune diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus.
Cullinan Therapeutics will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum, presenting insights into their clinical-stage therapeutic assets targeting autoimmune diseases and cancer.
Cullinan Therapeutics announced ongoing clinical trials for CLN-978 and velinotamig in autoimmune diseases, shared zipalertinib oncology results, and appointed two new board members while maintaining a strong cash position of $510.9 million.
Cullinan Therapeutics received approval from the European Medicines Agency to initiate a Phase 1 trial of its bispecific CD19 T cell engager CLN-978 in patients with rheumatoid arthritis. The trial will be conducted at research institutions in Germany and Italy, and CLN-978 is also being studied for systemic lupus erythematosus.
Cullinan Therapeutics reported progress in its pipeline, including initial clinical data for CLN-978 in Systemic Lupus Erythematosus expected in Q4 2025 and positive results from the pivotal Phase 2b study of zipalertinib. The company ended 2024 with $606.9 million in cash, providing runway into 2028.
